Coherus Presents Preclinical Data for CHS-1000, a Novel Anti

–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–

Related Keywords

San Diego , California , United States , Coherus Biosciences , Narendiran Rajasekaran , Theresa Lavallee , Jodi Sievers , Jami Taylor , Abbvie Inc , Exchange Commission On , Nasdaq , Exchange Commission , Coherus Biosciences Inc , Amgen Inc , Corporate Communications , Chief Development Officer , Immune Checkpoints , Inhibitory Molecules , Fc Modified Igg , Private Securities Litigation Reform Act , Coheru Annual Report , Contact Information ,